Medarex Revenue and Competitors

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Medarex's estimated annual revenue is currently $18.3M per year.(i)
  • Medarex's estimated revenue per employee is $155,000

Employee Data

  • Medarex has 118 Employees.(i)
  • Medarex grew their employee count by 3% last year.

Medarex's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$8.5M55-21%N/AN/A
#2
$0.2M10%N/AN/A
#3
$8.5M55-29%N/AN/A
#4
$108.5M5002%N/AN/A
#5
$0.8M50%N/AN/A
#6
$0.6M40%N/AN/A
#7
$14.7M68-23%$206.4MN/A
#8
$492.2M1503-15%$568MN/A
#9
$1.1M7-42%N/AN/A
#10
$4.5M290%N/AN/A
Add Company

What Is Medarex?

Medarex is a biopharmaceutical company focused on the discovery, development, and potential commercialization of fully human antibody-based therapeutics to treat life- threatening and debilitating diseases, including cancer, inflammation, autoimmune and infectious diseases. Medarex applies its UltiMAb® technology and product development and clinical manufacturing experience to generate, support and potentially commercialize a broad range of fully human antibody products for itself and its partners. Medarex is committed to building value by developing a diverse pipeline of antibody products to address the world's unmet healthcare needs.

keywords:N/A

N/A

Total Funding

118

Number of Employees

$18.3M

Revenue (est)

3%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Medarex News

2022-04-13 - Oxford BioTherapeutics Grants Third Exclusive License to ...

... as other world leaders in antibody development (such as Amgen, Immunogen, WuXi, Medarex (BMS), Alere (Abbott), BioWa, and Nerviano).

2022-04-06 - Bradycardia Market to Witness Growth Acceleration | Alchem ...

... Katsura Chemical, Lepu Medical, Livanova, Medarex, Medico, Medtronic, Merck, Minsheng Group, Nexus Pharmaceuticals, Nihon Kohden, Oscor,...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$26M118-2%N/A
#2
$17.3M119-7%N/A
#3
$21.6M1201%N/A
#4
$17.5M12173%N/A
#5
$17.7M122-3%N/A